S100A2 and cervical cancer: This gap could be filled by future experiments examining whether the overexpression of S100A2 replicates the effects of hypoxia in driving an aggressive cervical cancer phenotype and if its overexpression counteracts the action of PD-L1 inhibitor pembrolizumab in reducing cancer phenotype.